As an adjuvant treatment, durvalumab was able to extend survival in patients who failed conventional chemoradiotherapy, asserting the use of PD-L1 inhibitors should be used in treatment regimens for SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.